| Shiny C Joice, FNP-BC | |
|
800 5th Ave Ste 500, Fort Worth, TX 76104-7304 | |
| (817) 250-4280 | |
| (817) 788-5261 |
| Full Name | Shiny C Joice |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 8 Years |
| Location | 800 5th Ave Ste 500, Fort Worth, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013423839 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | AP133946 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas Health Physicians Group | 4385535954 | 1182 |
News Archive
Scientists from Australia's national science agency, CSIRO, can now detect gluten in any food and show which grain it comes from, making it easier for food companies to correctly label their products.
Amsterdam Molecular Therapeutics (AMT) Holding N.V. a leader in the development of gene based therapies, today announced that its gene therapy product incorporating siRNA sequences into microRNA scaffolds to silence Apolipoprotein B100 (AAV-miApoB) was able to significantly lower plasma cholesterol levels in vivo over a period of 18 weeks. These preliminary results suggest that this approach could lead to a treatment for high cholesterol in humans
Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).
Women who were born preterm have a higher risk of giving birth to preterm children, according to a study, published in the journal Obstetrics & Gynecology, from researchers of the CHU Sainte-Justine and the University of Montreal.
AgaMatrix, Inc. and sanofi-aventis today announced that they have signed a long-term agreement for the development, supply and commercialization of blood glucose monitoring (BGM) solutions. Under the terms of the agreement, AgaMatrix and sanofi-aventis will co-develop innovative solutions in diabetes management that incorporate AgaMatrix's WaveSense™ technology. Sanofi-aventis will commercialize through its Global Diabetes Division such integrated solutions for patients with diabetes, along with current sanofi-aventis insulins and delivery devices.
› Verified 4 days ago
| Entity Name | Texas Health Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174573596 PECOS PAC ID: 4385535954 Enrollment ID: O20040323000759 |
News Archive
Scientists from Australia's national science agency, CSIRO, can now detect gluten in any food and show which grain it comes from, making it easier for food companies to correctly label their products.
Amsterdam Molecular Therapeutics (AMT) Holding N.V. a leader in the development of gene based therapies, today announced that its gene therapy product incorporating siRNA sequences into microRNA scaffolds to silence Apolipoprotein B100 (AAV-miApoB) was able to significantly lower plasma cholesterol levels in vivo over a period of 18 weeks. These preliminary results suggest that this approach could lead to a treatment for high cholesterol in humans
Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).
Women who were born preterm have a higher risk of giving birth to preterm children, according to a study, published in the journal Obstetrics & Gynecology, from researchers of the CHU Sainte-Justine and the University of Montreal.
AgaMatrix, Inc. and sanofi-aventis today announced that they have signed a long-term agreement for the development, supply and commercialization of blood glucose monitoring (BGM) solutions. Under the terms of the agreement, AgaMatrix and sanofi-aventis will co-develop innovative solutions in diabetes management that incorporate AgaMatrix's WaveSense™ technology. Sanofi-aventis will commercialize through its Global Diabetes Division such integrated solutions for patients with diabetes, along with current sanofi-aventis insulins and delivery devices.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shiny C Joice, FNP-BC 800 5th Ave Ste 500, Fort Worth, TX 76104-7304 Ph: (817) 250-4280 | Shiny C Joice, FNP-BC 800 5th Ave Ste 500, Fort Worth, TX 76104-7304 Ph: (817) 250-4280 |
News Archive
Scientists from Australia's national science agency, CSIRO, can now detect gluten in any food and show which grain it comes from, making it easier for food companies to correctly label their products.
Amsterdam Molecular Therapeutics (AMT) Holding N.V. a leader in the development of gene based therapies, today announced that its gene therapy product incorporating siRNA sequences into microRNA scaffolds to silence Apolipoprotein B100 (AAV-miApoB) was able to significantly lower plasma cholesterol levels in vivo over a period of 18 weeks. These preliminary results suggest that this approach could lead to a treatment for high cholesterol in humans
Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).
Women who were born preterm have a higher risk of giving birth to preterm children, according to a study, published in the journal Obstetrics & Gynecology, from researchers of the CHU Sainte-Justine and the University of Montreal.
AgaMatrix, Inc. and sanofi-aventis today announced that they have signed a long-term agreement for the development, supply and commercialization of blood glucose monitoring (BGM) solutions. Under the terms of the agreement, AgaMatrix and sanofi-aventis will co-develop innovative solutions in diabetes management that incorporate AgaMatrix's WaveSense™ technology. Sanofi-aventis will commercialize through its Global Diabetes Division such integrated solutions for patients with diabetes, along with current sanofi-aventis insulins and delivery devices.
› Verified 4 days ago
Mrs. Amy Michelle Medalie, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 4405 River Oaks Blvd, Fort Worth, TX 76114 Phone: 817-624-1770 Fax: 817-625-1287 | |
Valerie Elise Ward, RN, CPNP-PC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2755 Miller Ave, Fort Worth, TX 76105 Phone: 817-534-7110 Fax: 817-413-0521 | |
Maria Sybil Gagliano, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 6000 Bryant Irvin Rd, Fort Worth, TX 76132 Phone: 866-389-2727 | |
Kristi E Tucker, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 801 7th Ave, Fort Worth, TX 76104 Phone: 682-885-1475 Fax: 682-885-7520 | |
Lacy Pitchford, CPNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1263 W Rosedale St Ste 200, Fort Worth, TX 76104 Phone: 817-336-4896 Fax: 817-332-2805 | |
Mary Agnes Johnson, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1400 8th Ave, Fort Worth, TX 76104 Phone: 817-922-7070 | |
Susan Akberzie, CPNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1401 W Pulaski St, Fort Worth, TX 76104 Phone: 682-885-8012 Fax: 682-885-8014 |